US 12,351,878 B2
Identification of HER2 mutations in lung cancer and methods of treatment
William Hendricks, Phoenix, AZ (US); Muhammed Murtaza, Phoenix, AZ (US); and Gwendolen Lorch, Columbus, OH (US)
Assigned to THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, Phoenix, AZ (US); and OHIO STATE UNIVERSITY, Columbus, OH (US)
Appl. No. 17/413,488
Filed by THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, Phoenix, AZ (US); and OHIO STATE UNIVERSITY, Columbus, OH (US)
PCT Filed Dec. 11, 2019, PCT No. PCT/US2019/065715
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/123642, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/778,282, filed on Dec. 11, 2018.
Prior Publication US 2022/0056535 A1, Feb. 24, 2022
Int. Cl. C12Q 1/6886 (2018.01); A61K 45/06 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 45/06 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 18 Claims
 
1. A method of treating lung cancer in a canine subject, comprising the steps of:
receiving a biological sample from the subject;
analyzing the biological sample for one or more missense mutations in HER2, wherein the one or more missense mutations in HER2 comprises V659E, A664T and/or K676E;
and treating the subject with an inhibitor of HER2 if the one or more missense mutations is present.